CJC-1295 no DAC / lpamorelin
Batch #: CJCIPA-5-601
Verified Potency: 5.31mg / 6.49mg
$99.00
A 1:1 blend of CJC-1295 no DAC and Ipamorelin designed for research on growth hormone secretion and pituitary signaling pathways.
Ships by
Calculating...
Disclaimer
For Research Use Only. Not for human consumption or therapeutic treatment.
About CJC-1295 no DAC / lpamorelin
This blend combines CJC-1295 no DAC, a long-acting GHRH analog, with Ipamorelin, a selective ghrelin receptor (GHSR-1a) agonist. Together, they are frequently used in research models to study coordinated stimulation of growth hormone release through both hypothalamic and pituitary pathways. CJC-1295 is often examined for its extended half-life and sustained GH/IGF-1 signaling, while Ipamorelin is valued for its receptor selectivity and limited impact on cortisol and prolactin. The 5mg/5mg formulation provides a balanced profile for investigating synergistic GH pulse dynamics, metabolic regulation, and endocrine feedback mechanisms.
Product Specifications
CJC-1295 (5mg) and Ipamorelin (5mg) Lyophilized Powder in 3ml vial
Application
Growth hormone axis, GHRH, and ghrelin pathway combination research
Appearance
Solid, white powder in 3mL glass ampule
Chemical Formula
CJC-1295: C165H271N47O46 Ipamorelin: C38H49N9O5
CAS number
CJC-1295: 863288-34-0 Ipamorelin: 170851-70-4
Molecular Weight
CJC-1295: ~3367.9 g/mol Ipamorelin: ~711.9 g/mol
FAQs
What is the CJC-1295 no DAC and Ipamorelin blend?
This blend combines two peptides that act through different receptor pathways in the growth hormone axis. CJC-1295 no DAC is a 29-amino acid GHRH analog that activates the growth hormone-releasing hormone receptor on pituitary somatotrophs. Ipamorelin is a pentapeptide growth hormone secretagogue that activates the ghrelin receptor (GHS-R1a). The blend is formulated as a single lyophilized powder in a sealed 3mL glass ampule.
Why are CJC-1295 no DAC and Ipamorelin studied together?
Published research demonstrates that GHRH analogs and ghrelin receptor agonists produce synergistic growth hormone release when co-administered because they activate two distinct receptor signaling pathways that converge on pituitary somatotroph cells. CJC-1295 no DAC increases cyclic AMP via the GHRH receptor, while ipamorelin activates the inositol phospholipid pathway via GHS-R1a. The combined effect produces a greater amplitude growth hormone pulse than either peptide administered alone.
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It is selective for the ghrelin receptor (GHS-R1a) on pituitary somatotrophs and produces growth hormone release without the appetite-stimulating effects or cortisol and prolactin elevation associated with other GHS-R1a agonists like GHRP-6. This selectivity makes ipamorelin a studied tool for isolating growth hormone axis effects from secondary endocrine responses.
Does this blend affect cortisol or prolactin levels in research?
Ipamorelin is studied specifically because it does not produce the cortisol and prolactin elevations seen with GHRP-6 and GHRP-2 at growth hormone-releasing doses. CJC-1295 no DAC acts through the GHRH receptor, which also does not stimulate cortisol or prolactin secretion. The combination of these two peptides is therefore used in research protocols where growth hormone release is the target variable and confounding endocrine effects need to be minimized.
Can I buy the CJC-1295 no DAC and Ipamorelin blend for research?
Limitless Peptides sells the CJC-1295 no DAC and Ipamorelin blend as a lyophilized powder in a sealed 3mL glass ampule. The product is Janoshik verified for identity, potency, and purity. This blend is sold for research use only and is not approved for human consumption. The product page includes the certificate of analysis and a link to the independent Janoshik verification report.
